rs2682818/MiR-618 is a novel marker associated with increased risk of breast cancer in the Iranian population
DOI:
https://doi.org/10.2298/ABS210808039NKeywords:
breast cancer, miR-618, polymorphism, ARMS-PCR, Iranian populationAbstract
Paper description:
- micro-RNA-618 (miR-618) plays a major role in a variety of tumors, including breast cancer.
- rs2682818/miR-618 polymorphism in breast cancer patients and healthy individuals was genotyped to examine the association between this polymorphism and breast cancer prevalence.
- correlation between rs2682818/miR-618 and the risk of breast cancer is statistically significant (OR=2.97, P=0.0003).
- rs2682818/miR-618 could be considered as an important marker associated with the risk of breast cancer
Abstract: The presence of single nucleotide variations in the coding region of micro-RNA (miRNA)-encoding genes plays a significant role in the expression and function of these molecules in oncogenesis and cancer. The association of rs2682818 in miR-618 with increased risk of breast cancer was investigated in the Iranian population. rs2682818/miR-618 was genotyped using amplification-refractory mutation system PCR (ARMS-PCR) in 200 healthy individuals and patients with breast cancer. The data revealed the presence of Hardy-Weinberg equilibrium (HWE) for this marker. The frequency of alleles C and A was 70% and 30%, respectively, in healthy individuals; the frequency of alleles C and A was 44% and 56%, respectively, in patients with breast cancer. Analysis of odd ratios showed that the rs2682818/miR-618 polymorphism is associated with increased probability of breast cancer and is statistically significant (OR=2.97, P=0.0003). The data suggest that rs2682818/miR-618 could be considered a novel marker of increased risk of breast cancer.
Downloads
References
DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA: Cancer J Clin. 2017;67(6):439-48.
https://doi.org/10.3322/caac.21412
Karimi P, Hematti S, Ghaedi K, Kamali E, Tavassoli M. Association of the Polymorphism of the Estro-gen-Related Receptor Gamma (ERRγ) Gene and the Risk of Breast Cancer in the Population of Isfahan. Genet Millenn. 2013;29(4);11.
Youlden DR, Cramb SM, Yip CH, Baade PD. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol Med. 2014;11(2):101-15.
Keshavarzi F, Javadi GR, Nafissi N, Akbari ME, Yassaee VR, Sharafi Farzad M, Zeinali, S. BRCA1 and BRCA2 genetic testing in breast and/or ovarian cancer families in Iran. Cell J (Yakhteh). 2010;12(3):329-40.
De Abreu FB, Wells WA, Tsongalis GJ. The emerging role of the molecular diagnostics laboratory in breast cancer personalized medicine. Am J Pathol. 2013;183(4):1075-83.
https://doi.org/10.1016/j.ajpath.2013.07.002
Shi M, Guo N. MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer. Cancer Treat Rev. 2009;35(4):328-34.
https://doi.org/10.1016/j.ctrv.2008.12.002
Fu SW, Chen L, Man Y-g. miRNA biomarkers in breast cancer detection and management. J Cancer. 2011;2:116.
https://doi.org/10.7150/jca.2.116
Wittmann J, Jäck H-M. Serum microRNAs as powerful cancer biomarkers. Biochimica et Biophysica Acta (BBA)- Rev Cancer. 2010;1806(2):200-7.
https://doi.org/10.1016/j.bbcan.2010.07.002
Yu D-C, Li Q-G, Ding X-W, Ding Y-T. Circulating microRNAs: potential biomarkers for cancer. Int J Mol Sci. 2011;12(3):2055-63.
https://doi.org/10.3390/ijms12032055
Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. microRNAs in cancer management. Lancet Oncol. 2012;13(6):e249-58.
https://doi.org/10.1016/S1470-2045(12)70073-6
Ranganathan K, Sivasankar V. MicroRNAs-Biology and clinical applications. J Oral Maxillofac Pathol. 2014;18(2):229.
https://doi.org/10.4103/0973-029X.140762
Rawlings-Goss RA, Campbell MC, Tishkoff SA. Global population-specific variation in miRNA associated with cancer risk and clinical biomarkers. BMC Med Genomics. 2014;7(1):53.
https://doi.org/10.1186/1755-8794-7-53
Afsharzadeh SM, Ardebili SMM, Seyedi SM, Fathi NK, Mojarrad M. Association between rs11614913, rs3746444, rs2910164 and occurrence of breast cancer in Iranian population. Meta Gene. 2017;11:20-5.
https://doi.org/10.1016/j.mgene.2016.11.004
Baranwal S, Alahari SK. miRNA control of tumor cell invasion and metastasis. Int J Cancer. 2010;126(6):1283-90.
https://doi.org/10.1002/ijc.25014
Suzuki H, Maruyama R, Yamamoto E, Kai M. DNA methylation and microRNA dysregulation in cancer. Mol Oncol. 2012;6(6):567-78.
https://doi.org/10.1016/j.molonc.2012.07.007
Nguyen-Dien GT, Smith RA, Haupt LM, Griffiths LR, Nguyen HT. Genetic polymorphisms in miRNAs targeting the estrogen receptor and their effect on breast cancer risk. Meta Gene. 2014;2:226-36.
https://doi.org/10.1016/j.mgene.2014.01.002
Willis R. Targeted cancer therapy: vital oncogenes and a new molecular genetic paradigm for cancer initiation progression and treatment. Int J Mol Sci. 2016;17(9):1552.
https://doi.org/10.3390/ijms17091552
Qi P, Wang L, Zhou B, Yao W, Xu S, Zhou Y, Xie ZB. Associations of miRNA polymorphisms and expression levels with breast cancer risk in the Chinese population. Genet Mol Res. 2015;14(2):6289-96.
https://doi.org/10.4238/2015.June.11.2
Vallian Broojeni S, Kheradmand P. Bioligy, function and detection of microRNA. J Lab Diag. 2015;7(28):33-40.
Salisbury BA, Pungliya M, Choi JY, Jiang R, Sun XJ, Stephens JC. SNP and haplotype variation in the human genome. Mutat Res. 2003;526(1-2):53-61.
https://doi.org/10.1016/S0027-5107(03)00014-9
Ebrahimi N, Moeinifar N, Vallian S. rs1542705-67,992,843-1,050,239 represents a novel informative haplotype at the SMPD1 locus in the Iranian population. Meta Gene. 2020;25:100744.
https://doi.org/10.1016/j.mgene.2020.100744
Sung H, Zhang B, Choi J-Y, Long J, Park SK, Yoo K-Y, Noh D-Y, Ahn S-H, Zheng W, Kang D. Common genetic variants in the microRNA biogenesis pathway are not associated with breast cancer risk in Asian women. Cancer Epidemiol Biomarkers Prev. 2012;21(8):1385-7.
https://doi.org/10.1158/1055-9965.EPI-12-0600
Pipan V, Zorc M, Kunej T. MicroRNA polymorphisms in cancer: a literature analysis. Cancers. 2015;7(3):1806-14.
https://doi.org/10.3390/cancers7030863
Kabirizadeh S, Azadeh M, Mirhosseini M, Ghaedi K, Tanha HM. The SNP rs3746444 within mir-499a is associated with breast cancer risk in Iranian population. J Cell Immunother. 2016;2(2):95-7.
https://doi.org/10.1016/j.jocit.2016.08.003
Mulrane L, McGee SF, Gallagher WM, O'Connor DP. miRNA dysregulation in breast cancer. Cancer Res. 2013;73(22):6554-62.
https://doi.org/10.1158/0008-5472.CAN-13-1841
Catucci I, Yang R, Verderio P, Pizzamiglio S, Heesen L, Hemminki K, Sutter C, Wappenschmidt B, Dick M, Arnold N, Bugert P,Niederacher D, Meindl A, Schmutzler RK, Bartram CC, Ficarazzi F, Tizzoni L, Zaffaroni D, Manoukian S, Barile M, Pierotti MA, Radice P, Burwinkel B, Peterlongo P. Evaluation of SNPs in miR‐146a, miR196a2 and miR‐499 as low‐penetrance alleles in German and Italian familial breast cancer cases. Hum Mutat. 2010;31(1):E1052-7.
https://doi.org/10.1002/humu.21141
Catucci I, Verderio P, Pizzamiglio S, Bernard L, Dall'olio V, Sardella D, Ravagnani F, Galastri L, Barile M, Peissel B, Zaffaroni D, Manoukian S, Radice P, Peterlongo P. The SNP rs895819 in miR-27a is not associated with familial breast cancer risk in Italians. Breast Cancer Res Treat. 2012;133(2):805-7.
https://doi.org/10.1007/s10549-012-2011-y
Pastrello C, Polesel J, Della Puppa L, Viel A, Maestro R. Association between hsa-mir-146a genotype and tumor age-of-onset in BRCA1/BRCA2-negative familial breast and ovarian cancer patients. Carcinogenesis. 2010;31(12):2124-6.
https://doi.org/10.1093/carcin/bgq184
Hu Z, Liang J, Wang Z, Tian T, Zhou X, Chen J, Miao R, Wang Y, Wang X, Shen H. Common genetic variants in pre‐microRNAs were associated with increased risk of breast cancer in Chinese women. Hum Mutat. 2009;30(1):79-84.
https://doi.org/10.1002/humu.20837
Zhang M, Jin M, Yu Y, Zhang S, Wu Y, Liu H, Liu H, Chen B, Li Q, Ma X, Chen K. Associations of miRNA polymorphisms and female physiological characteristics with breast cancer risk in Chinese population. Eur J Cancer Care. 2012;21(2):274-80.
https://doi.org/10.1111/j.1365-2354.2011.01308.x
Alshatwi AA, Shafi G, Hasan TN, Syed NA, Al-Hazzani AA, Alsaif MA, Alsaif AA. Differential expression profile and genetic variants of microRNAs sequences in breast cancer patients. PLoS One. 2012;7(2):e30049.
https://doi.org/10.1371/journal.pone.0030049
Kontorovich T, Levy A, Korostishevsky M, Nir U, Friedman E. Single nucleotide polymorphisms in miRNA binding sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high‐risk women. Int J Cancer. 2010;127(3):589-97.
https://doi.org/10.1002/ijc.25065
Ebrahimi N, Borujeni SV. Analysis of Genetic Variation of rs1542705 Marker in SMPD1 Gene Region as an Informative Marker for Molecular Diagnosis of Niemann-Pick Disease in Isfahan Population. J Arak Uni Med Sci. 2016;19(6):1-10
Fazeli Z, Vallian S. Phylogenetic relationship analysis of Iranians and other world populations using allele frequencies at 12 polymorphic markers. Mol Biol Rep. 2012;39(12):11187-99.
https://doi.org/10.1007/s11033-012-2028-7
Morales S, Gulppi F, Gonzalez-Hormazabal P, Fernandez-Ramires R, Bravo T, Reyes JM, Gomez F, Waugh E, Jara L. Association of single nucleotide polymorphisms in Pre-miR-27a, Pre-miR-196a2, Pre-miR-423, miR-608 and Pre-miR-618 with breast cancer susceptibility in a South American population. BMC Genet. 2016;17(1):109.
https://doi.org/10.1186/s12863-016-0415-0
Yi L, Yuan Y. MicroRNA-618 modulates cell growth via targeting PI3K/Akt pathway in human thyroid carcinomas. Indian J Cancer. 2015;52(7):186.
https://doi.org/10.4103/0019-509X.186577
Song X-L, Tang Y, Lei X-H, Zhao S-C, Wu Z-Q. miR-618 inhibits prostate Cancer migration and invasion by targeting FOXP2. J Cancer. 2017;8(13):2501.
https://doi.org/10.7150/jca.17407
Fu A, Hoffman AE, Liu R, Jacobs DI, Zheng T, Zhu Y. Targetome profiling and functional genetics implicate miR-618 in lymphomagenesis. Epigenetics. 2014;9(5):730-7.
https://doi.org/10.4161/epi.27996
Miller S, Dykes D, Polesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215.
https://doi.org/10.1093/nar/16.3.1215
Little S. Amplification‐refractory mutation system (ARMS) analysis of point mutations. Curr Protoc Hum Genet. 1995;7(1):9.8.1-12.
https://doi.org/10.1002/0471142905.hg0908s07
Ye S, Dhillon S, Ke X, Collins AR, Day IN. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res. 2001;29(17):e88-e.
https://doi.org/10.1093/nar/29.17.e88
Shen J, Ambrosone CB, DiCioccio RA, Odunsi K, Lele SB, Zhao H. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis. 2008;29(10):1963-6.
https://doi.org/10.1093/carcin/bgn172
Morales S, Gulppi F, Gonzalez-Hormazabal P, Fernandez-Ramires R, Bravo T, Reyes JM, Gomez F, Waugh E, Jara L Association of single nucleotide polymorphisms in Pre-miR-27a, Pre-miR-196a2, Pre-miR-423, miR-608 and Pre-miR-618 with breast cancer susceptibility in a South American population. BMC Genet. 2016;17(1):1-10.
https://doi.org/10.1186/s12863-016-0415-0
Feng X, Ji D, Liang C, Fan S. Does miR-618 rs2682818 variant affect cancer susceptibility? Evidence from 10 case-control studies. Biosci Rep. 2019;39(8).
https://doi.org/10.1042/BSR20190741
Cheng Q, Zhang X, Xu X, Lu X. MiR-618 inhibits anaplastic thyroid cancer by repressing XIAP in one ATC cell line. Ann Endocrinol (Paris). 2014;75(4):187-93.
https://doi.org/10.1016/j.ando.2014.01.002
Ebrahimi N, Vallian Borujeni S. Analysis of genetic variation of rs1542705 marker in SMPD1 gene region as an informative marker for molecular diagnosis of Niemann-Pick disease in Isfahan population. J Arak Uni Med Sci. 2016;19(6):1-10.
Chamgordani LE, Ebrahimi N, Amirmahani F, Vallian S. CG/CA genotypes represent novel markers in the NPHS2 gene region associated with nephrotic syndrome. J Genetics. 2020;99(1):1-7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Archives of Biological Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.
